Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects

By sjmartinez • July 5, 2022

Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler JHW, Alves M, Stock C, Distler O. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respir Res. 2022 Jul 5;23(1):178. doi: 10.1186/s12931-022-02095-6. PMID: 35790961; PMCID: PMC9258095.

Tags: Connective tissue diseases, Publications, Pulmonary fibrosis, Rheumatology, systemic Scleroderma, Vital capacity

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]